RAND CAPITAL CORP — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 58/100
What the filing says
Rand Capital (market cap ~$15.2M) reported Q2 2026 results with mixed signals: deployed $6.9M into two new investments (Feature Healthcare $4.5M at 12%+2% PIK; Termite Guy $2.1M debt + $300K equity at 13%+1% PIK), realized $959K gain on Applied Image exit, but portfolio deteriorated significantly—BMP Swanson wrote off $2.5M, non-accruals pressured yield from 11.3% to 8.98%, and investment income fell 13% YoY to $1.4M. NAV per share declined from $17.57 (Dec 2025) to $17.33 (Jun 2026); net assets fell $724K to $51.5M. Dividend maintained at $0.29/share.
Why this rating
Portfolio writedowns ($2.5M BMP Swanson) and non-accrual headwinds meaningful relative to $51.5M NAV (5%), but offset by new deployments, gain realization, and stable dividend. Real deterioration in portfolio quality but manageable liquidity ($12.4M available credit) and continued capital deployment. Ordinary BDC stress, not trajectory-altering.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.